The 2023 Conference on the Development of China's Pharmaceutical Industry, co-sponsored by the Ministry of Industry and Information Technology, Beijing Municipal People's Government, National Health Commission, State-owned Assets Supervision and Administration Commission of the State Council, National Administration of Traditional Chinese Medicine, and National Medical Products Administration, was held in Beijing from November 17 to 19. During the event, several authoritative lists that have attracted much attention in the industry were released at the 40th China Pharmaceutical Industry Information Annual Conference, one of the core thematic forums of the event. Fosun Pharma, with its sustained innovation and comprehensive competitiveness, set a new record and ranked 2nd in the 2022 Top 100 Companies in China's Pharmaceutical Industry, jumping by 2 places from the previous year.

The Top 100 Companies in China's Pharmaceutical Industry is one of the most authoritative and representative evaluation activities in the pharmaceutical industry in China, which objectively reflects the economic operation and changing pattern of the industry. The appraisal of candidates and their ranking are subject to several procedures, including the preliminary review of materials, the first expert review, the second expert review, review by the Ministry of Industry and Information Technology, and comprehensive examination and approval. The 2022 list features 30 companies with an annual turnover exceeding RMB 10 billion, an increase of two compared with 2021. The top 100 companies have demonstrated great development resilience in the changeable internal and external environment.

Fosun Pharma is a global innovation-driven pharmaceutical and healthcare industry group with a history of nearly 30 years. It directly operates businesses including pharmaceuticals, medical devices, medical diagnosis, and healthcare services. As a shareholder of Sinopharm Co., Ltd., Fosun Pharma expands its areas in the pharmaceutical distribution and retail business. Placing pharmaceuticals at the core of its business, Fosun Pharma has worked on innovative R&D since 2009. With over ten years of continuous investment, the company has established an open and globalized innovative R&D system, promoting the R&D and launch of many innovative technologies and products that mark "the first attempt" in China and the world. Fosun Pharma continuously enriches its innovative product pipeline through independent R&D, cooperative development, license-in, and in-depth incubation. Its innovative products mainly cover core treatment fields such as oncology (both solid and hematologic tumors), autoimmunity, central nervous system, and chronic disease (liver disease, metabolism issues, and renal disorders).

In recent years, Fosun Pharma has constantly optimized its innovative product structure, with a number of new products and indications approved for marketing. The portfolio of innovative products has been further expanded, the product structure has been continuously refined, and the revenue from innovative products has maintained rapid growth. By the end of 2022, revenue from new and sub-new products, including Han Si Zhuang, Han Qu You, and Su Ke Xin, accounted for over 30% of the revenue in the pharmaceutical manufacturing segment. Among them, Han Si Zhuang^® (Serplulimab Injection), the world's first approved anti-PD-1 mAb for the first-line treatment of small cell lung cancer (SCLC) independently developed by Fosun Pharma, has benefited over 40,000 patients in China. By the end of Q3 2023, Han Si Zhuang^® has obtained approvals for four indications, namely microsatellite instability-high (MSI-H) solid tumors, squamous non-small cell lung cancer (NSCLC), extensive-stage small cell lung cancer (ES-SCLC), and esophageal squamous cell carcinomas (ESCC). Fosun Pharma continues to deepen the differentiated and multi-dimensional layout of Han Si Zhuang^® in lung cancer, gastrointestinal tumors, and other fields, aiming to benefit more patients.

In June 2023, China's first approved CAR-T cell therapy Yi Kai Da^® (Axicabtagene Ciloleucel Injection) received additional approval for the second-line indication (for the treatment of adult patients with large B-cell lymphoma (r/r LBCL) that is refractory to first-line immunochemotherapy or that relapses within 12 months of first-line immunochemotherapy) in the Chinese mainland, which will benefit more lymphoma patients in China. So far, Fosun Kite has established over 140 Yi Kai Da^® high-standard treatment centers in 25 provinces, regions, and cities throughout China. In addition, it has continuously improved the manufacturing process and enhanced the efficacy of the drug, achieving outstanding performance with drug safety surpassing the international leading level and a complete response rate exceeding 55%. Currently, this product has benefited over 600 patients with relapsed or refractory large B-cell lymphoma.

The continuous optimization of the revenue structure is due to Fosun Pharma's intensified R&D investment over the years. In the first three quarters of 2023, Fosun Pharma's investment in R&D amounted to RMB 4.291 billion, a year-on-year increase of 13.67%. Of this total, R&D expenses reached RMB 3.155 billion, a year-on-year increase of 10.22%.As of the first half of 2023, Fosun Pharma had over 70 projects for drugs under development, including innovator drugs and biosimilars. Among them, 5 innovator drugs (indications) and 10 generic drugs (indications) were approved and launched, 4 innovator drugs/biosimilars (indications) and 34 generic drugs (indications) had applied for launch (NDA), and 7 innovator drugs/biosimilars (indications) were approved for clinical trials (IND) in the Chinese mainland.

Innovation, upgrading, and collaboration are the intrinsic factors and driving forces behind the breakthrough growth of the Top 100 pharmaceutical companies, which also demonstrate the development advantages of China's pharmaceutical industry. With the leapfrog development of the domestic pharmaceutical industry, Fosun Pharma is about to enter its 30th year. In the future, Fosun Pharma will uphold the development model of "Innovation Transformation, Integrated Operation and Steady Growth", adhere to innovation and globalization, assume its due responsibilities in high-quality development, and further contribute to the growth of China's pharmaceutical industry.